A San Francisco study associated fentanyl detection with benzodiazepine metabolites, while limiting its conclusions to a specific population and period.
Repeated specimens and self-report
The investigators collected up to six monthly samples from 245 women with housing instability during 2016–2019. Fentanyl metabolites appeared at 35 of 1,050 visits. Most positive visits also involved reported heroin or opioid medication use. Benzodiazepine metabolites were independently associated with fentanyl detection in adjusted analysis.
Association does not reveal intent or source
The findings cannot determine whether a benzodiazepine was prescribed, knowingly combined with fentanyl, or responsible for a clinical event. Urine detection windows differed from the self-report period, and the study did not separately assess known fentanyl use. Sampling from one city limits transfer to other locations or later drug markets. Its results support interpreting co-detection alongside a detailed history, rather than using a positive result to infer motivation, product contamination, exact timing, or a particular contribution to toxicity.
Source paper
Original analysis of the supplied journal article, identified as PMC7063812.
Leave a Reply